Genflow Biosciences PLC CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest strategic moves as it released its 2024 results. Leire highlighted significant progress across Genflow’s R&D portfolio, particularly around MASH (metabolic dysfunction-associated steatohepatitis), animal health, and novel ageing-related targets.
He confirmed Genflow has received positive feedback from the FDA regarding its plans for a clinical trial in MASH, which will begin directly in patients rather than healthy volunteers. “We will be allowed to start directly with MASH patients,” Leire said, adding this could improve the value impact by demonstrating both safety and potential efficacy.
Leire also discussed a major €4 million funding commitment from the Wallonia region to support the development of GF-1002, with additional equity funding secured to progress the pipeline. Importantly, Genflow is also advancing a randomised, comparative dog study with multiple endpoints, aiming for a shorter-term exit strategy via licensing or sale. “This study of dogs is very good proof of concept,” said Leire. He noted it’s being run by contract research organisation Syngene.
Beyond MASH and the animal health program, Genflow is working on projects in Werner syndrome and sarcopenia. It is also advancing its intellectual property strategy, having moved its patents on MASH and the SIRT6 centenarian gene into the national phase — a step Leire said could raise the company’s valuation.
Watch the full video to learn more about Genflow’s near- and long-term pipeline developments.
Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe to our channel, and hit the bell to get notified of our latest content.
#GenflowBiosciences #MASH #FDAapproval #BiotechInvestment #SIRT6 #GeneTherapy #AnimalHealth #Sarcopenia #WernerSyndrome #ClinicalTrials #BiotechNews #ProactiveInvestors
